NanoString nCounter Vantage Assays

Nanostring Technologies has launched its nCounter Vantage assay portfolio to power 3D biology experiments in cancer research. The portfolio includes two new RNA panels for the detection of fusion genes in lung cancer and leukemia samples, two new protein panels covering solid tumor biology and immune-cell signaling, and one new DNA panel for the detection of single nucleotide variations. The assays allow for multiplexed, digital analysis of DNA, RNA, and protein simultaneously in a single experiment, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.